1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development: the design of small molecule and protein therapeutics. The firm is structured around decreasing the time and cost factor in drug development while also improving the success rate of achieving effective drugs: innovative medicines needed by patients. Currently, two drug discovery engines are in use enabling the design both of small molecule and of protein therapeutics not, so far, yet utilized in AI drug discovery space. Current focus of applying the firm's novel drug discovery approach involves several areas of investigation: neuroscience, infectious disease, immunology and oncology. With two drug discovery engines - ELVIS⢠and ROSALYND⢠- enabling the design of both small molecule and protein therapeutics -- an unmatched capability in the AI drug discovery space - the firm's therapeutic "area-agnostic, end-to-end technology" powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. At this point, the firm's technology andapproach to drug discovery address several areas including, but not limited to, neuroscience, infectious disease, immunology and oncolo